Aboueshia M, Hussein MH, Attia AS, Swinford A, Miller P, Omar M et al (2021) Cancer and COVID-19: analysis of patient outcomes. Future Oncol 17(26):3499–3510. https://doi.org/10.2217/fon-2021-0121
Alharthy A, Aletreby W, Faqihi F, Balhamar A, Alaklobi F, Alanezi K et al (2021) Clinical characteristics and predictors of 28-day mortality in 352 critically Ill patients with COVID-19: a retrospective study. J Epidemiol Glob Health 11(1):98–104. https://doi.org/10.2991/jegh.k.200928.001
Alwani M, Yassin A, Al-Zoubi RM, Aboumarzouk OM, Nettleship J, Kelly D et al (2021) Sex-based differences in severity and mortality in COVID-19. Rev Med Virol 31(6):e2223. https://doi.org/10.1002/rmv.2223
Atas N, Eroglu GA, Sodan HN, Ozturk BO, Babaoglu H, Satis H et al (2021) Long-term safety and efficacy of anakinra and canakinumab in patients with familial Mediterranean fever: a single-centre real-life study with 101 patients. Clin Exp Rheumatol 39(5):30–36. https://doi.org/10.55563/clinexprheumatol/815tdt
Balkhair A, Al-Zakwani I, Al Busaidi M, Al-Khirbash A, Al Mubaihsi S, BaTaher H et al (2021) Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study. Int J Infect Dis 103:288–296. https://doi.org/10.1016/j.ijid.2020.11.149
Bami S, Vagrecha A, Soberman D, Badawi M, Cannone D, Lipton JM et al (2020) The use of anakinra in the treatment of secondary hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 67(11):e28581. https://doi.org/10.1002/pbc.28581
Bozzi G, Mangioni D, Minoia F, Aliberti S, Grasselli G, Barbetta L et al (2021) Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: an observational cohort study. J Allergy Clin Immunol 147(2):561-566.e564. https://doi.org/10.1016/j.jaci.2020.11.006
Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D et al (2020) Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol 2(6):e325–e331. https://doi.org/10.1016/s2665-9913(20)30127-2
Cavalli G, Larcher A, Tomelleri A, Campochiaro C, Della-Torre E, De Luca G et al (2021) Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. Lancet Rheumatol 3(4):e253–e261. https://doi.org/10.1016/s2665-9913(21)00012-6
COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines (2022) National Institutes of Health. Retrieved from https://www.covid19treatmentguidelines.nih.gov/. Accessed 8 Aug 2022
Dinarello CA (2011) Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117(14):3720–3732. https://doi.org/10.1182/blood-2010-07-273417
Fan X, Nowell DL (2011) Using propensity score matching in educational research. Gift Child Q 55(1):74–79. https://doi.org/10.1177/0016986210390635
Feld J, Tremblay D, Thibaud S, Kessler A, Naymagon L (2020) Ferritin levels in patients with COVID-19: a poor predictor of mortality and hemophagocytic lymphohistiocytosis. Int J Lab Hematol 42(6):773–779. https://doi.org/10.1111/ijlh.13309
Gabay C, Lamacchia C, Palmer G (2010) IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol 6(4):232–241. https://doi.org/10.1038/nrrheum.2010.4
Gavand PE, Serio I, Arnaud L, Costedoat-Chalumeau N, Carvelli J, Dossier A et al (2017) Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: a study of 103 episodes in 89 adult patients. Autoimmun Rev 16(7):743–749. https://doi.org/10.1016/j.autrev.2017.05.010
Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M (2018) CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med 24(6):731–738. https://doi.org/10.1038/s41591-018-0041-7
Gilboa M, Bornstein G, Ben-Zvi I, Grossman C (2020) Macrophage activation syndrome complicating rheumatic diseases in adults: case-based review. Rheumatol Int 40(4):663–669. https://doi.org/10.1007/s00296-019-04393-7
Grom AA, Horne A, De Benedetti F (2016) Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol 12(5):259–268. https://doi.org/10.1038/nrrheum.2015.179
Hanff TC, Mohareb AM, Giri J, Cohen JB, Chirinos JA (2020) Thrombosis in COVID-19. Am J Hematol 95(12):1578–1589. https://doi.org/10.1002/ajh.25982
Hong D, Yang Z, Han S, Liang X, Ma K, Zhang X (2014) Interleukin 1 inhibition with anakinra in adult-onset still disease: a meta-analysis of its efficacy and safety. Drug Des Devel Ther 8:2345–2357. https://doi.org/10.2147/dddt.S73428
Hu B, Huang S, Yin L (2021) The cytokine storm and COVID-19. J Med Virol 93(1):250–256. https://doi.org/10.1002/jmv.26232
Karakike E, Dalekos GN, Koutsodimitropoulos I, Saridaki M, Pourzitaki C, Papathanakos G et al (2022) ESCAPE: an open-label trial of personalized immunotherapy in critically lll COVID-19 patients. J Innate Immun 14(3):218–228. https://doi.org/10.1159/000519090
Kyriazopoulou E, Huet T, Cavalli G, Gori A, Kyprianou M, Pickkers P et al (2021) Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. Lancet Rheumatol 3(10):e690–e697. https://doi.org/10.1016/s2665-9913(21)00216-2
Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR (2020) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents 55(3):105924. https://doi.org/10.1016/j.ijantimicag.2020.105924
López-Reyes A, Martinez-Armenta C, Espinosa-Velázquez R, Vázquez-Cárdenas P, Cruz-Ramos M, Palacios-Gonzalez B et al (2020) NLRP3 inflammasome: the stormy link between obesity and COVID-19. Front Immunol 11:570251. https://doi.org/10.3389/fimmu.2020.570251
Mehta P, Cron RQ, Hartwell J, Manson JJ, Tattersall RS (2020) Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome. Lancet Rheumatol 2(6):e358–e367. https://doi.org/10.1016/s2665-9913(20)30096-5
Ñamendys-Silva SA, Alvarado-Ávila PE, Domínguez-Cherit G, Rivero-Sigarroa E, Sánchez-Hurtado LA, Gutiérrez-Villaseñor A et al (2021) Outcomes of patients with COVID-19 in the intensive care unit in Mexico: a multicenter observational study. Heart Lung 50(1):28–32. https://doi.org/10.1016/j.hrtlng.2020.10.013
Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA et al (2011) Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 63(2):545–555. https://doi.org/10.1002/art.30128
Phadke O, Rouster-Stevens K, Giannopoulos H, Chandrakasan S, Prahalad S (2021) Intravenous administration of anakinra in children with macrophage activation syndrome. Pediatr Rheumatol Online J 19(1):98. https://doi.org/10.1186/s12969-021-00585-3
Saag KG, Khanna PP, Keenan RT, Ohlman S, Osterling Koskinen L, Sparve E et al (2021) A randomized, phase II study evaluating the efficacy and safety of anakinra in the treatment of gout flares. Arthritis Rheumatol 73(8):1533–1542. https://doi.org/10.1002/art.41699
Seyed Hosseini E, Riahi Kashani N, Nikzad H, Azadbakht J, Hassani Bafrani H, Haddad Kashani H (2020) The novel coronavirus disease-2019 (COVID-19): mechanism of action, detection and recent therapeutic strategies. Virology 551:1–9. https://doi.org/10.1016/j.virol.2020.08.011
Tang L, Yin Z, Hu Y, Mei H (2020) Controlling cytokine storm is vital in COVID-19. Front Immunol 11:570993. https://doi.org/10.3389/fimmu.2020.570993
Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M et al (2020) Hematological findings and complications of COVID-19. Am J Hematol 95(7):834–847. https://doi.org/10.1002/ajh.25829
Vora SM, Lieberman J, Wu H (2021) Inflammasome activation at the crux of severe COVID-19. Nat Rev Immunol 21(11):694–703. https://doi.org/10.1038/s41577-021-00588-x
Webb BJ, Peltan ID, Jensen P, Hoda D, Hunter B, Silver A et al (2020) Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study. Lancet Rheumatol 2(12):e754–e763. https://doi.org/10.1016/S2665-9913(20)30343-X
WHO (2020) Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. WHO, Geneva
Zhao X, Li Y, Ge Y, Shi Y, Lv P, Zhang J et al (2021) Evaluation of nutrition risk and its association with mortality risk in severely and critically ill COVID-19 patients. JPEN J Parenter Enteral Nutr 45(1):32–42. https://doi.org/10.1002/jpen.1953
Zou LX, Zhu Y, Sun L, Ma HH, Yang SR, Zeng HS et al (2020) Clinical and laboratory features, treatment, and outcomes of macrophage activation syndrome in 80 children: a multi-center study in China. World J Pediatr 16(1):89–98. https://doi.org/10.1007/s12519-019-00256-0
留言 (0)